The big SpaceX mega IPO is getting closer, and with a $1.75 trillion expected valuation (plus or minus a couple hundred billion or so), there’s sure to be a flood of investors who will need to sell something in order to load up on opening day. Undoubtedly, some of the hardcore Elon Musk fans might ... 4 Reasons Why SpaceX’s First Trading Day Might Be Hard to Sit Out
The big SpaceX mega IPO is getting closer, and with a $1.75 trillion expected valuation (plus or minus a couple hundred billion or so), there’s sure to be a flood of investors who will need to sell something in order to load up on opening day. Undoubtedly, some of the hardcore Elon Musk fans might ... 4 Reasons Why SpaceX’s First Trading Day Might Be Hard to Sit Out
Intellia Therapeutics ( NTLA ) on Wednesday said it priced an underwritten public offering of 16.74M shares at $10.75 each, for expected gross proceeds of about $180M. Shares down -11% in premarket. The stock closed at $13.2 on Tuesday. The company is selling all shares in the offering. It also granted underwriters a 30-day option to purchase up to an additional 2.51M shares at the same price, les...
Intellia Therapeutics ( NTLA ) on Wednesday said it priced an underwritten public offering of 16.74M shares at $10.75 each, for expected gross proceeds of about $180M. Shares down -11% in premarket. The stock closed at $13.2 on Tuesday. The company is selling all shares in the offering. It also granted underwriters a 30-day option to purchase up to an additional 2.51M shares at the same price, less discounts and commissions. Jefferies, Goldman Sachs, and Citigroup are acting as joint book-running managers. More on Intellia Therapeutics Intellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And Doubt Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema - Slideshow Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema Transcript Intellia Therapeutics launches $150M public stock offering Intellia jumps as FDA lifts clinical hold on nex-z for ATTR-CM
Shares of SoFi Technologies (NASDAQ:SOFI) are down roughly 9% in premarket trading on Wednesday, April 29, after the digital bank reported Q1 2026 results before market open (BMO). The fintech firm delivered another headline beat, yet the tape is showing the same reflex investors have come to dread. SOFI stock closed Tuesday at $18.36 and ... SoFi Slides 9% After Q1 Earnings: Is the Sell-On-Beat P...
Shares of SoFi Technologies (NASDAQ:SOFI) are down roughly 9% in premarket trading on Wednesday, April 29, after the digital bank reported Q1 2026 results before market open (BMO). The fintech firm delivered another headline beat, yet the tape is showing the same reflex investors have come to dread. SOFI stock closed Tuesday at $18.36 and ... SoFi Slides 9% After Q1 Earnings: Is the Sell-On-Beat Pattern Repeating Again?
designer491/iStock via Getty Images Redwood Trust ( RWT ), a mortgage REIT, and Castlelake, a global credit investor, announced on Wednesday a joint venture to grow Redwood’s Sequoia platform and expand prime jumbo mortgage loan buying. The JV plans to purchase up to $8B of high-quality home loans. Under the setup, Sequoia will source, review, and package eligible mortgage loans, focusing on high-...
designer491/iStock via Getty Images Redwood Trust ( RWT ), a mortgage REIT, and Castlelake, a global credit investor, announced on Wednesday a joint venture to grow Redwood’s Sequoia platform and expand prime jumbo mortgage loan buying. The JV plans to purchase up to $8B of high-quality home loans. Under the setup, Sequoia will source, review, and package eligible mortgage loans, focusing on high-quality assets to ensure smooth and disciplined execution. Redwood Trust ( RWT ) via Sequoia bought ~$100B in loans and turned over $50B+ into securities, while Castlelake has invested over ~$10B in real estate loans since 2024. Source: Press Release More on Redwood Trust Redwood Trust: Change In Delinquencies And Disclosures Make Me Pause On Baby Bonds (Downgrade) Redwood Trust Now Has 4 Notes Available: All Rated Hold Redwood Trust: 12% Dividend And Discount To Book Redwood Trust Q1 2026 Earnings Preview Redwood Trust expects core operating earnings above dividend in 2026 as record $23B volume drives platform expansion
Oklo (NYSE: OKLO) has become one of the market's most compelling nuclear energy stories, driven by AI power demand, policy momentum, and a major deal that has sparked serious investor excitement. But the stock's valuation already assumes significant future success, which makes th
Oklo (NYSE: OKLO) has become one of the market's most compelling nuclear energy stories, driven by AI power demand, policy momentum, and a major deal that has sparked serious investor excitement. But the stock's valuation already assumes significant future success, which makes th
Amphenol ( APH ) shares surged more than 7% in premarket trading on Wednesday after the electronic connector manufacturer reported stronger-than-expected results and guidance. For the first quarter, which ended March 31, Amphenol said it earned an adjusted $1.06 per share as revenue rose 58.4% year-over-year to come in at $7.62B. Analysts had expected the company to earn $0.94 per share on $7.08B ...
Amphenol ( APH ) shares surged more than 7% in premarket trading on Wednesday after the electronic connector manufacturer reported stronger-than-expected results and guidance. For the first quarter, which ended March 31, Amphenol said it earned an adjusted $1.06 per share as revenue rose 58.4% year-over-year to come in at $7.62B. Analysts had expected the company to earn $0.94 per share on $7.08B in revenue. Adjusted operating margin during the period was 27.3%, while operating and free cash flow came in at $1.1B and $831M, respectively. “We are pleased to have closed the first quarter of 2026 with record sales and Adjusted Diluted EPS, both exceeding the high end of our guidance,” said Amphenol President and CEO R. Adam Norwitt in a statement . “Sales increased from prior year by 58%, driven by strong organic growth in most of our end markets, including exceptional organic growth in the IT datacom market, as well as contributions from the company's acquisition program. We also booked record orders in the quarter, resulting in a book-to-bill of 1.24:1. The Company realized strong profitability during the quarter with adjusted operating margin reaching 27.3%. We are extremely proud of the company's outstanding performance.” Looking to the second-quarter, Amphenol expects to earn between $1.14 and $1.16 per share on an adjusted basis, ahead of the $1.05 analysts had expected. Sales are forecast to be between $8.1B and $8.2B, above the $7.7B estimate. The company will host a conference call at 1 p.m. EST to discuss the results. More on Amphenol Amphenol: Strong Growth Supported By Hyperscalers Amphenol: A Blue-Chip Compounder With Sustainable Competitive Advantages And AI Tailwinds Amphenol: Strong Q4 Results Reinforce Structural Growth Thesis Amphenol Non-GAAP EPS of $1.06 beats by $0.11, revenue of $7.62B beats by $530M Amphenol Q1 2026 Earnings Preview
CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ: CENX) will report first quarter 2026 earnings on Thursday, May 7, 2026, after market close. The news release will be issued through GlobeNewswire.
CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ: CENX) will report first quarter 2026 earnings on Thursday, May 7, 2026, after market close. The news release will be issued through GlobeNewswire.
(RTTNews) - Zebra Technologies Corporation (ZBRA), a provider of automatic identification and data solutions, Wednesday announced that its corporate venture capital unit, Zebra Ventures is making a strategic investment in Apera AI, a provider of 4D Vision for industrial robots.
(RTTNews) - Zebra Technologies Corporation (ZBRA), a provider of automatic identification and data solutions, Wednesday announced that its corporate venture capital unit, Zebra Ventures is making a strategic investment in Apera AI, a provider of 4D Vision for industrial robots.